Skip to main content
Home

Search


NEI on Social Media | Search A-Z | en español | Text size S M L
  • About NEI
    • NEI Research Accomplishments
    • Budget and Congress
    • About the NEI Director
    • History of the NEI
    • NEI 50th Anniversary
    • NEI Women Scientists Advisory Committee (WSAC)
    • Board of Scientific Counselors
    • National Advisory Eye Council (NAEC)
    • Donating to the NEI

    Menu About NEI Block

     Contact Us

     Visiting the NIH Campus

    Mission Statement

    As part of the federal government’s National Institutes of Health (NIH), the National Eye Institute’s mission is to “conduct and support research, training, health information dissemination, and other programs with respect to blinding eye diseases, visual disorders, mechanisms of visual function, preservation of sight, and the special health problems and requirements of the blind.”

  • News & Events
    • Events Calendar
    • NEI Press Releases
    • News from NEI Grantees
    • Spokesperson bios
    • Statistics and Data
    • Resources for the media

    Pressroom Contacts

    Dustin Hays - Chief, Science Communication
    dustin.hays@nih.gov

    Kathryn DeMott, Media Relations
    Kathryn.DeMott@nih.gov

    NEI Office of Communications
    (301)496-5248

  • Health Information
    • Frequently asked questions
    • Clinical Studies
    • Spanish Language Information
    • Publications Catalog
    • Photos and Images
  • Grants and Funding
    • Extramural Research
    • Division of Extramural Science Programs
    • Division of Extramural Activities

    Extramural Contacts

    National Eye Institute
    Division of Extramural Research
    6700B Rockledge Dr., MSC 6914
    Bethesda, MD 20892
    (FedEx, UPS, and other courier services use: Bethesda MD 20817)
    301-451-2020

  • Research at NEI
    • Office of the Scientific Director
    • Office of the Clinical Director
    • Laboratories, Sections and Units
    • eyeGENE
    • Division of Epidemiology and Clinical Applications

    Office of the Scientific Director

    Sheldon S. Miller, Ph.D., Scientific Director
    David M. Schneeweis, Ph.D., Deputy Scientific Director

    Office of the Clinical Director

    Brian P. Brooks, M.D, Ph.D., Clinical Director
    Emily Y. Chew, M.D., Deputy Clinical Director

  • Education Programs
    • National Eye Health Education Program (NEHEP)
    • Diabetic Eye Disease Education Program
    • Glaucoma Education Program
    • Low Vision Education Program
    • Hispanic/Latino Program
    • Vision and Aging Program
    • African American Program
  • Training and Jobs
    • Jobs
    • NEI Summer Intern Program
    • Diversity In Vision Research & Ophthalmology (DIVRO)
    • Student Training Programs

    To search for current job openings visit HHS USAJobs

Home » News » Statements » Vision Not Improved By Surgery for Complications of Age-Related Macular Degeneration
Listen

Topics

Age-Related Macular Degeneration (AMD)
AIDS-related eye disease (cytomegalovirus [CMV] retinitis)
Amblyopia
Anophthalmia and Microphthalmia
Appointments
Astigmatism
Audacious Goals Challenge
Awards
Behçet’s Disease of the Eye
Bietti's Crystalline Dystrophy
Blepharitis
Blepharospasm
Cataracts
Clinical Studies
coloboma
Color Blindness
Convergence Insufficiency (CI)
Cornea
Diabetic Eye Disease
Dry Eye
Education Programs
Eye Cancer
Eye Surgery
Floaters
Gene
Glaucoma
Healthy Vision Month
Hispanic/Latino Americans
Histoplasmosis
Hyperopia
Idiopathic Intracranial Hypertension
Infancy
Infectious Eye Disease
Leber Congenital Amaurosis (LCA)
Low Vision
Macular Degeneration
Macular Edema
Macular Hole
Macular Pucker
Myopia
NEI
NEI Remembers
NEI Website
Optic Nerve Disorders
Pink Eye (Conjunctivitis)
Preschool
Rare Diseases
Refractive Errors
Refractive Surgery
Retina
Retinal Disease
Retinitis Pigmentosa
Retinoblastoma
Retinopathy of Prematurity (ROP)
Retinoschisis
Spanish
Spanish
Stargardt Disease
Stem Cells
Usher Syndrome
Uveitis/Inflammatory Eye Disease
Vision Screening
World Sight Day

Vision Not Improved By Surgery for Complications of Age-Related Macular Degeneration

Archived Page

The information on this page is archived and provided for reference purposes only. It was current when it was produced, but may now be out-of-date. Persons having difficulty accessing this information may contact kcl@nei.nih.gov for assistance. For reliable, current information on this and other topics, we recommend that you visit the National Eye Institute website index.

Contact: 
National Eye Institute 301-496-5248 berberichs@nei.nih.gov
11/01/04

Vision does not improve substantially for patients with age-related macular degeneration (AMD) who undergo surgery to remove lesions of new blood vessels, scar tissue, or possible bleeding beneath the retina, according to results of nationwide clinical trials sponsored by the National Eye Institute (NEI), part of the National Institutes of Health.

In older adults, the most common cause of irreversible and severe loss of vision is called wet AMD. Unwanted blood vessels and scar tissue grow beneath and into the macula, the central part of the retina responsible for perceiving fine visual detail. Treatment options for improving vision are limited for wet AMD.

The NEI-funded Submacular Surgery Trials (SST) investigated outcomes of surgery being practiced by retinal surgeons to remove lesions–scientifically known as choroidal neovascularization–that are linked with AMD and other causes. Before the trials began in 1997, the risks and benefits of surgery to improve or stabilize vision of patients with such conditions had not been well defined.

“While the trials were not successful in doing what we wanted to do for these patients with AMD, that is, to keep their vision stable or to improve it,” says NEI Director Paul A. Sieving, M.D., Ph.D., “the study provides valuable information to doctors and their patients. But, we will not stop there. The NEI will continue to conduct and support the best research possible while the search continues for new effective treatments for AMD,” Sieving added.

In the November issue of the journal Ophthalmology, four of a total of six main result papers on the SST will be published. The four papers address surgery for two groups of AMD patients.

In the first group, surgery did not improve vision for half of 454 patients who had centrally located lesions that were not predominantly blood, when compared with half who did not receive surgery but did receive regular eye examinations. This finding confirms a growing clinical impression among many retinal surgeons that submacular surgery is not helpful for these commonly-found lesions in AMD patients’ eyes.

Surgery was also not beneficial for a second group of patients–those with more extensive bleeding under the retina. This second group involved 336 patients who were assigned randomly to either surgery or careful observation. Among these patients, vision had not stabilized or improved after two years in those who underwent surgery to remove lesions and associated blood (which was the primary test of the trials), when compared with patients with no surgery.

Other treatments for CNV due to AMD include laser photocoagulation and photodynamic therapy. Both laser photocoagulation and photodynamic therapy have been shown to reduce the risk of moderate and severe loss of vision in some patients with CNV associated with AMD. But these treatments usually are not used for eye lesions similar to those of patients who took part in the SST.

According to estimates published by the NEI-sponsored Age-Related Eye Disease Study, approximately 200,000 individuals in the United States develop the wet, or neovascular, form of AMD each year. This form occurs in less than 20 percent of all patients with AMD but is responsible for approximately 90 percent of cases with severe vision loss.

The SST built on an hypothesis (emanating from earlier NEI-sponsored SST pilot studies) that surgical removal of CNV lesions may halt enlargement of the visual defect. Further, their removal might spare vital photoreceptors in the central macula from damage and thereby allow nearby ocular structures to function normally.

Patients in the trials also answered questionnaires and surveys to record how their eye condition affected their quality of life, before and after the surgery. Not surprisingly, SST patients reported a high degree of quality of life impairment due to poor vision.

A total of 25 clinical centers collaborated in the trials for the AMD patients with CNV. Two other SST papers, on surgery for CNV due to two causes other than AMD, will be published in the November 2004 Archives of Ophthalmology. The target conditions for those papers were CNV caused by ocular histoplasmosis syndrome or by unknown causes (idiopathic).

More on the 454 patients with AMD-related CNV

  • Patients were 50 years or older; median age of 77.
  • Each patient had a subfoveal neovascular lesion. The surgeons classified the lesions as ‘classic’ choroidal neovascularization–a pattern seen on photographs of the back of the eye taken as the new blood vessels fill with fluorescein dye.
  • Prospective patients with prior treatment for CNV were ineligible.
  • All patients, surgery and observation alike, were given follow-up examinations at 3-, 6-, 12-, and 24-month periods after enrollment. Adverse effects were reported immediately following an examination. A separate Adverse Event Review Committee classified such events.
  • Rhegmatogenous retinal detachment occurred in twelve surgery eyes and one observation eye.
  • Of the surgery patients with no previous cataract surgery, 39 percent received cataract surgery by the 24-month examination, compared with five percent of the observation patients.

More on the 336 patients with more extensive bleeding from AMD

  • Patients were 50 years or older with a median age of 79.
  • Eligible patients had lesions of 8.9 mm or larger, at least half of which was blood under the center of the macula. They also had best-corrected vision of 20/100 to light perception in the study eye.
  • Patients with previous eye treatments with laser photocoagulation were permitted in the trial.
  • Two years after surgery, 44 percent of surgery eyes with no prior cataract surgery needed cataract surgery.
  • Rhegmatogenous retinal detachment developed in 27 surgery eyes compared with only three of the observed eyes. The SST leadership called this a relatively high level of risk that increased in patients with larger lesions and worse visual acuity levels.”

Journal Citations:

Submacular Surgery Trials (SST) Research Group. Surgery for subfoveal choroidal neovascularization in age-related macular degeneration: ophthalmic findings, SST Report Number 11. Ophthalmology 111: 1967-1980, 2004.

Submacular Surgery Trials (SST) Research Group. Surgery for subfoveal choroidal neovascularization in age-related macular degeneration: quality of life findings, SST Report Number 12. Ophthalmology 111: 1981-1992, 2004.

Submacular Surgery Trials (SST) Research Group. Surgery for hemorrhagic choroidal neovascular lesions of age-related macular degeneration: ophthalmic findings, SST Report Number 13. Ophthalmology 111: 1993-2006, 2004.

Submacular Surgery Trials (SST) Research Group. Surgery for hemorrhagic choroidal neovascular lesions of age-related macular degeneration: ophthalmic findings, SST Report Number 14. Ophthalmology 111: 2007-2014, 2004.

# # #

Citations

  • Hawkins BS, Bressler NM, Miskala PH, Bressler SB, Holekamp NM, Marsh MJ, Redford M, Schwartz SD, Sternberg P Jr, Thomas MA, Wilson DJ, Submacular Surgery Trials (SST) Research Group. Surgery for Subfoveal Choroidal Neovascularization in Age-Related Macular Degeneration: Ophthalmic Findings, SST Report No. 11. Ophthalmology. 2004 Nov. <a href=’http://www.ncbi.nlm.nih.gov/pubmed/15522362”>PubMed
  • Miskala PH, Bass EB, Bressler NM, Childs AL, Hawkins BS, Mangione CM, Marsh MJ, Submacular Surgery Trials (SST) Research Group. Surgery for Subfoveal Choroidal Neovascularization in Age-Related Macular Degeneration: Quality-of-Life Findings: SST Report No. 12. Ophthalomology. 2004 Nov. PubMed
  • Bressler NM, Bressler SB, Childs AL, Haller JA, Hawkins BS, Lewis H, MacCumber MW, Marsh MJ, Redford M, Sternberg P Jr, Thomas MA, Williams GA, Submacular Surgery Trials (SST) Research Group. Surgery for Hemorrhagic Choroidal Neovascular Lesions of Age-Related Macular Degeneration: Ophthalmic Findings: SST Report No. 13. Ophthalmology. 2004 Nov. PubMed
  • Childs AL, Bressler NM, Bass EB, Hawkins BS, Mangione CM, Marsh MJ, Miskala PH, Submacular Surgery Trials (SST) Research Group. Surgery for Hemorrhagic Choroidal Neovascular Lesions of Age-Related Macular Degeneration: Quality-of-Life: SST Report No. 14. Ophthalmology. 2004 Nov. <a href=’http://www.ncbi.nlm.nih.gov/pubmed/15522365’”>PubMed
  • NEI Home
  • Contact Us
  • A-Z Site Map
  • NEI on Social Media
  • Information in Spanish (Información en español)
  • Website, Social Media Policies and Other Important Links
  • NEI Employee Emergency Information
  • NEI Intranet (Employees Only)
  • Department of Health and Human Services
  • The National Institutes of Health
  • USA.gov

*PDF files require the free Adobe® Reader® software for viewing.

Technical questions about this website can be addressed to the NEI Website Manager.